Outcomes
ADVERSE EFFECTS, GASTROINTESTINAL DISORDERS
The primary outcome was the MDS-UPDRS score of the subjects at week 12. Secondary outcomes were the MDS-UPDRS score at weeks 0, 4, and 8, safety (adverse effects) at weeks 0, 4, 8, and 12, and evaluation for gastrointestinal disorders (including the IBS-SSS, GSRS, Bristol stool form scale, and IBS-QOL scale scores) and evaluation for mental health (including the PHQ-9 scale, GDS-15 scale, GAD-7 scale, Montreal Cognitive Assessment, Mini-mental State Examination scores) at weeks 0, 4 8 and 12, and alterations in gut microbiota at weeks 0, 4 and 12, including alpha diversity (Shannon index) and beta diversity (PCoA) at the genus level, microbial community composition among donors, the FMT group, and the placebo group.